News
RDY
14.08
+0.79%
0.11
BUZZ-India ADRs gain after Trump announces trade deal with India
Reuters · 6d ago
Dr. Reddy’s Schedules Nuvama Investor Conference Meetings in Mumbai on February 9, 2026
TipRanks · 6d ago
Weekly Report: what happened at RDY last week (0126-0130)?
Weekly Report · 6d ago
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
TipRanks · 01/30 13:15
Coya Therapeutics Commences ~$11.1M Offering Of 2.522M Common Shares At $4.40/Share; Dr. Reddy's Laboratories And Greenlight Capital Are Investors In Offering
Benzinga · 01/30 13:10
Dr. Reddy’s Q3 Earnings Call: Growth Amid Margin Strain
TipRanks · 01/27 00:09
Dr. Reddy’s Russian Subsidiary Faces VAT Reclassification Penalty Deemed Immaterial
TipRanks · 01/26 11:27
Dr. Reddy's Russia Subsidiary Faces RUB 20 Million VAT Penalty
Reuters · 01/26 11:08
Weekly Report: what happened at RDY last week (0119-0123)?
Weekly Report · 01/26 10:13
Dr. Reddy's Laboratories Releases Q3 FY2025 Earnings Call Audio Recording
Reuters · 01/22 11:38
INDIA STOCKS-Indian shares gain after Trump drops EU tariff threat over Greenland
Reuters · 01/22 10:25
Dr. Reddy's GAAP EPS of ₹14.52, revenue of ₹87.27B
Seeking Alpha · 01/22 04:38
Dr Reddy's Laboratories Q3 EPS $0.16, Inline, Sales $978.820M Beat $978.100M Estimate
Benzinga · 01/21 23:03
Dr. Reddy's Q3FY26 EBITDA at INR 11.2 billion, down 23.5 percent
Reuters · 01/21 17:29
Dr. Reddy's wins India nod for generic Ozempic
Seeking Alpha · 01/21 15:56
'Dr Reddy's to Start Selling Generic Ozempic in India From March' - Bloomberg
Benzinga · 01/21 15:06
DR REDDY'S EXEC: EXPECT SEMAGLUTIDE LAUNCH IN INDIA, FOLLOWED BY EMERGING MARKETS, THEN SUBSEQUENTLY CANADA
Reuters · 01/21 12:28
BUZZ-PREVIEW-Analysts expect Dr Reddy's to post first profit drop in five quarters
Reuters · 01/21 04:01
Here are the major earnings before the open Wednesday
Seeking Alpha · 01/20 23:00
Dr. Reddy's Q3 Earnings Preview
Seeking Alpha · 01/20 16:21
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.